Search
Now showing items 1-10 of 21
Ubiquitin-mediated regulation of necroptosis
(Institute of Cancer Research (University Of London), 2020-01-31)
Regulated cell death is a fundamental cellular process that is critical for the development and survival of multicellular organisms. Cell death and inflammation are essential to restore tissue homeostasis following tissue ...
Defining the role of SF3B1K700E mutations in ER+ breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Mutations in SF3B1, a component of the RNA splicing machinery, underpin a number of aggressive cancers. Hotspot mutations in SF3B1 are present in around 3% of breast cancers, are enriched in oestrogen receptor positive ...
Late recurrence in ER+ breast cancer - refining risk prediction beyond 5 years
(Institute of Cancer Research (University Of London), 2021-11-30)
ER positive (ER+) breast cancer has the potential to recur many years following diagnosis. Predicting who is most at risk of recurrence and when this may occur is complex. Risk prediction incorporates clinical, pathological ...
Identification of novel targets for the treatment of endocrine-resistant breast cancer
(Institute of Cancer Research (University Of London), 2022-05-31)
While endocrine therapy is an effective, well-tolerated treatment for oestrogen receptor positive (ER-positive) breast cancer, a large proportion of initial responders will develop hormone therapy resistance, and relapse. ...
Targeting the tumour microenvironment with endosialin-directed CAR T-cells
(Institute of Cancer Research (University Of London), 2022-05-31)
Advances in T-cell engineering have facilitated the generation of CAR T-cells that successfully deplete malignant cells of haematological cancers. However, attempts to target solid tumours with CAR T-cells have been hindered ...
Modulation of the tumour immune microenvironment by cancer-associated fibroblasts
(Institute of Cancer Research (University Of London), 2019-11-30)
The breast tumour microenvironment (TME) consists of a variety of non-cancerous cell types that can promote or inhibit cancer progression. Cancer-associated fibroblasts (CAFs) represent a major component of the breast TME ...
Targeting RIPK1 ubiquitylation to promote anti-tumour immunity
(Institute of Cancer Research (University Of London), 2019-11-30)
Cancer heterogeneity is a key problem of current therapies leading to resistance. The way cancer cells die can lead to anti-cancer immunity, which is frequently referred to as "immunogenic" cell death. The aim of the project ...
Investigating a range of late effects of Hodgkin lymphoma treatments
(Institute of Cancer Research (University Of London), 2021-01-31)
Dramatic improvement in Hodgkin lymphoma (HL) survival rates over recent decades has come at significant cost: treatment-related late effects which are epitomised in female HL patients treated at young ages. The aims of ...
Selective autophagy receptors in pancreatic ductal adenocarcinoma
(Institute of Cancer Research (University Of London), 2022-07-06)
Pancreatic cancer accounted for 2.5% of all new cancers diagnosed worldwide in 2018, but remains disproportionally one of the most lethal cancers. Therefore, the development and validation of novel biomarkers (BMs), for ...
Circulating microRNA-652-3p as a biomarker of regorafenib resistance in metastatic colorectal cancer patients
(Institute of Cancer Research (University Of London), 2020-09-30)
MicroRNAs (miRNAs) are small non-coding RNAs involved in cell homeostasis. MiRNAs dysregulation has been linked with activation of oncogenic pathways, cancer progression and clinical outcome in metastatic colorectal cancer ...